![]()
|
|
|
Room for IMPROVER
December 2012
SHARING OPTIONS:
NEW YORK—It may not be the oddest couple to tackle better
ways of handling complex life-science data, but New York City-based tobacco
industry giant Philip Morris International (PMI) and
Armonk-N.Y.-based computing giant IBM certainly make for a novel-seeming pair
as they work toward the creation of their Industrial Methodology for Process Verification
in Research (IMPROVER).
The initiative is similar to ones
seen before, such as one that IBM lead earlier, called the
DREAM project (Dialogue on Reverse
Engineering Assessment and Methods), but IMPROVER looks specifically at developing
a more transparent and robust process for assessing complex scientific data
using a “wisdom of the crowds” approach in which teams of scientists from around
the world will compete in a series of scientific challenges. Through these
challenges, PMI and IBM say, those scientists will “actively contribute to the
development of an innovative method for verification of scientific data and
concepts in systems biology research.”
As for the “why?” of this
particular pairing, IBM has been involved in many healthcare and life-sciences
efforts before—some of them involving systems biology—and PMI is interested in
making less harmful tobacco products, with an eye toward using systems biology
and computational modeling as a way to predict the health risks of such
products. PMI’s efforts have been confounded to a large degree, as Dr. Hugh Browne,
director of research and development for PMI,
notes, by the fact there currently exists no standard
method of verifying the company’s
conclusions.
“What started us thinking
in this area is that as we’ve made significant investments in systems biology
at PMI, we’ve realized that one of the things science is really good at these
days is generating huge quantities of data in short periods of time,” Browne
explains. “And, if we look at the peer review process, we can see that it was
never really designed with systems biology or large, complex datasets in mind.
It occurred to us that there were other techniques that could be complementary
to peer review to allow the scientific community to get the most out of the
data that is generated and to still have that degree of rigor—complementary to
peer review, but beyond what the existing system is able to provide.”
From there, he said, PMI set about thinking who it could
partner with, and the Thomas J. Watson Research Center at IBM quickly hit the
top of the list, as the team there already had experience both with handling
big data and with crowdsourcing, such as with the DREAM project. The work
around IMPROVER—also known as SBV IMPROVER, with the SBV standing for systems
biology verification—began officially in 2009.
“We felt that with IBM’s capabilities and familiarity with
systems biology, they would be an ideal partner for PMI to think about how we
could move the approach to data like this in a direction where the data can be
reviewed and assessed in a way that traditional peer review alone simply
doesn’t allow for,” Browne says.
“Peer review isn’t coming to an end, but it does have its
limitations, especially when it comes to big data, because most people just
can’t deal with that complexity on their own or with just a few other people,”
notes IBM Research’s Dr. Jörg Sprengel. “What
we are doing is applicable to a lot of industries, including environmental,
animal health and food safety, but we think it’s particularly relevant to
pharma and biotech. That said, there is a lot of interest in some of those
other market segments, particularly with consumer products like nutrition,
cosmetics and veterinary, where they want to make certain claims—particularly
about health benefits—and need evidence to back those up.”
The ultimate goal is to create an
industry standard—a product to help make systems biology-related work more
efficient and useful. In the end, “SBV IMPROVER might bear some resemblance to
things like ISO 9000 accreditations,” Browne says, “where there is a clear
framework and methodologies published but the actual assessment is outsourced
to a third party. That could help speed time to market.”
The collaborative initiative’s first challenge, the
Diagnostic Signature Challenge, has already been completed after being launched
in March of this year, with members of the global scientific and academic
community invited to identify diagnostic signatures in four disease areas:
psoriasis, multiple sclerosis, chronic obstructive pulmonary disease and lung
cancer. The initial aim of the Diagnostic Signature Challenge was to verify
whether it is possible to extract robust diagnostic signatures for each of the
four diseases under investigation. If it was established that diagnostic
signatures can be identified, the next goal was to identify the best diagnostic
signature for each disease together with its associated discovery algorithm.
The research modality that IMPROVER employs “confronts
scientists with huge challenges to ensure that their conclusions are accurate,
robust and capable of translating through to innovative policies, processes and
products,” says Dr. Gustavo Stolovitzky, manager of functional genomics and
systems biology at the IBM Computational Biology Centre. “The outcome of the
Diagnostic Signature Challenge shows us that IMPROVER has the potential to
significantly influence how systems biology can be verified in industrial
contexts in the years to come.”
The next challenge, to be launched in the second quarter of
2013, will be the Species Translation Challenge.
“With our first challenge, we wanted to start as simple as
we could with something so complex, and confirm that our approach works, since
people do all kinds of things looking at data like this, but not usually in a
systematic fashion,” Sprengel says. “The next steps will be to move to a more
qualitative rather than quantitative point, and determine translatability from
model systems to human cell lines. The next level up from that will be to look
at more predictive goals.”
Using a crowdsourcing approach was
important in getting beyond peer review constraints but still retaining much of
the value of what peer review provides, Sprengel and Browne maintain.
“In the first challenge, there
were teams that performed very well in some areas but not as well in others,”
Sprengel notes. “Our intention is to get the best overall performers and
evaluate what they can offer to try and improve the approaches as much as we
can.” “If you look at the 54 teams that submitted entries
for the first challenge, they used subtly different approaches,” Browne
continues, “and that’s the ‘wisdom of the crowds’ from which you can take
elements of one solution and combine it with another and probably have a better
solution overall.” Code: E121204 Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|